Login to Your Account



CV Therapeutics' Ranexa: Odds For Approval Good'

By Randall Osborne


Monday, October 27, 2003
Though still waiting for an action letter from the FDA, CV Therapeutics Inc.'s news Thursday that an advisory panel has slated for Dec. 9 a review of Ranexa (ranolazine) for chronic angina was enough to boost the company's stock. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription